Lawrence I Golbe
Overview
Explore the profile of Lawrence I Golbe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
3783
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Xie T, Wills A, Liao C, Dale M, Ramsden D, Padmanaban M, et al.
Mov Disord
. 2022 Dec;
38(2):304-312.
PMID: 36573662
Background: Rapid development of downgaze palsy, the most specific symptom of progressive supranuclear palsy (PSP), has been associated with shorter survival in small studies. Objective: We hypothesized that the progression...
12.
Dam T, Boxer A, Golbe L, Hoglinger G, Morris H, Litvan I, et al.
Nat Med
. 2022 Oct;
29(11):2955-2956.
PMID: 36253611
No abstract available.
13.
14.
Wills A, Golbe L, Lang A, Xie T, Dale M, Espay A, et al.
Mov Disord
. 2022 Jul;
37(9):1960-1961.
PMID: 35810447
No abstract available.
15.
Wills A, Pantelyat A, Espay A, Chan J, Litvan I, Xie T, et al.
Mov Disord
. 2022 Apr;
37(6):1265-1271.
PMID: 35363932
Background: The reliability of the Progressive Supranuclear Palsy Rating Scale (PSPRS) using teleneurology has not been assessed. Objectives: To test whether removing items inadequately assessed by video would impact measurement...
16.
Dam T, Boxer A, Golbe L, Hoglinger G, Morris H, Litvan I, et al.
Nat Med
. 2021 Aug;
27(8):1451-1457.
PMID: 34385707
A randomized, double-blind, placebo-controlled, 52-week study (no. NCT03068468) evaluated gosuranemab, an anti-tau monoclonal antibody, in the treatment of progressive supranuclear palsy (PSP). In total, 486 participants dosed were assigned to...
17.
Bluett B, Pantelyat A, Litvan I, Ali F, Apetauerova D, Bega D, et al.
Front Neurol
. 2021 Jul;
12:694872.
PMID: 34276544
Progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS; the most common phenotype of corticobasal degeneration) are tauopathies with a relentless course, usually starting in the mid-60s and leading to death...
18.
Grotsch M, Respondek G, Colosimo C, Compta Y, Corvol J, Ferreira J, et al.
Mov Disord
. 2021 Jan;
36(5):1203-1215.
PMID: 33513292
Background: The Progressive Supranuclear Palsy Rating Scale is a prospectively validated physician-rated measure of disease severity for progressive supranuclear palsy. We hypothesized that, according to experts' opinion, individual scores of...
19.
Iankova V, Respondek G, Saranza G, Painous C, Camara A, Compta Y, et al.
Parkinsonism Relat Disord
. 2020 Sep;
78:200-203.
PMID: 32988736
Background: The International Parkinson and Movement Disorder Society-endorsed Progressive Supranuclear Palsy Study Group published clinical diagnostic criteria for progressive supranuclear palsy in 2017, aiming to optimize early, sensitive and specific...
20.
Golbe L, Ohman-Strickland P, Beisser E, Elghoul F
Mov Disord Clin Pract
. 2020 Aug;
7(6):664-671.
PMID: 32775512
Background: Progressive supranuclear palsy (PSP) causes major disability, shortens life, and as yet has no disease-modifying and little symptomatic treatment. A convenient prognostic tool is needed to assist patients, families,...